Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 for NF2-related Vestibular Schwannoma
NCT01345136Phase 2Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2015
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in vestibular schwannoma (VS), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Jul 2015; status: terminated.
02
Drugs
everolimus
03
Conditions
vestibular schwannoma (VS)
Beyond the preview
Go deeper on NCT01345136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01345136.